chr5-132604806-T-C
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 0P and 3B. BP4_ModerateBP6
The NM_005732.4(RAD50):āc.2525T>Cā(p.Val842Ala) variant causes a missense, splice region change. The variant allele was found at a frequency of 0.000402 in 1,604,444 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_005732.4 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RAD50 | NM_005732.4 | c.2525T>C | p.Val842Ala | missense_variant, splice_region_variant | 16/25 | ENST00000378823.8 | NP_005723.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAD50 | ENST00000378823.8 | c.2525T>C | p.Val842Ala | missense_variant, splice_region_variant | 16/25 | 1 | NM_005732.4 | ENSP00000368100.4 | ||
ENSG00000283782 | ENST00000640655.2 | c.2228T>C | p.Val743Ala | missense_variant, splice_region_variant | 17/26 | 5 | ENSP00000491596.2 |
Frequencies
GnomAD3 genomes AF: 0.000191 AC: 29AN: 152218Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000105 AC: 26AN: 248368Hom.: 0 AF XY: 0.0000819 AC XY: 11AN XY: 134234
GnomAD4 exome AF: 0.000424 AC: 616AN: 1452226Hom.: 1 Cov.: 30 AF XY: 0.000415 AC XY: 300AN XY: 722910
GnomAD4 genome AF: 0.000191 AC: 29AN: 152218Hom.: 0 Cov.: 32 AF XY: 0.000188 AC XY: 14AN XY: 74364
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 28, 2023 | The p.V842A variant (also known as c.2525T>C) is located in coding exon 16 of the RAD50 gene. The valine at codon 842 is replaced by alanine, an amino acid with similar properties. This change occurs in the first base pair of coding exon 16. This variant has been reported in multiple breast cancer case-control studies (Tommiska J et al. Int. J. Cancer, 2006 Jun;118:2911-6; Damiola F et al. Breast Cancer Res, 2014 Jun;16:R58; Young EL et al. J Med Genet, 2016 06;53:366-76). It has also been reported in 1/1358 non-cancer control individuals and in 0/57 cases, in a study looking at cancer predisposition mutations in patients with cutaneous melanoma and a history of at least two additional non-cutaneous melanoma primary cancers (Pritchard AL et al. PLoS One, 2018 Apr;13:e0194098). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Feb 19, 2014 | RAD50 has been only recently described in association with cancer predisposition and the risks are not well understood. This variant is denoted RAD50 c.2525T>C at the cDNA level, p.Val842Ala (V842A) at the protein level, and results in the change of a Valine to an Alanine (GTT>GCT). This variant was observed in an individual with breast cancer and a family history of breast cancer (Tommiska 2006). RAD50 Val842Ala was not observed at a significant allele frequency in the NHLBI Exome Sequencing Project. This variant is a conservative substitution of one neutral non-polar amino acid for another, altering a position that is well conserved through mammals and is located in a potential coil-coiled region (UniProt). In silico analyses predict this variant to have a benign effect on protein structure and function. At a molecular level, the impact of this missense variant on protein structure and function is not known and thus we consider this to be a variant of uncertain significance. Furthermore, based on the currently available information, cancer risks associated with this variant, and the RAD50 gene, remain unclear. - |
Nijmegen breakage syndrome-like disorder Uncertain:1
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | Oct 07, 2021 | - - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 05, 2020 | Variant summary: RAD50 c.2525T>C (p.Val842Ala) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. 4/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00011 in 279768 control chromosomes, predominantly at a frequency of 0.0002 within the Non-Finnish European subpopulation in the gnomAD database. The observed variant frequency within Non-Finnish European control individuals in the gnomAD database is approximately 3.2 fold of the estimated maximal expected allele frequency for a pathogenic variant in RAD50 causing Hereditary Breast And Ovarian Cancer Syndrome phenotype (6.3e-05), strongly suggesting that the variant is a benign polymorphism found primarily in populations of Non-Finnish European origin. c.2525T>C has been reported in the literature in individuals affected with breast cancer or non-Hodgkin lymphoma (Tommiska_2006, Schuetz_2009, Damiola_2014). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two ClinVar submitters (evaluation after 2014) cite the variant as uncertain significance and likely benign. Based on the evidence outlined above, the variant was classified as likely benign. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at